Unicycive Therapeutics, Inc.
UNCY
$0.6961
$0.05829.12%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 102.72% | -176.03% | 5.47% | 356.77% | -43.83% |
| Total Depreciation and Amortization | -52.46% | 63.41% | 55.70% | -244.87% | 531.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -163.14% | 509.51% | -146.04% | -11,616.67% | 17.22% |
| Change in Net Operating Assets | -196.30% | 51.83% | -1,481.27% | 106.73% | 1,980.22% |
| Cash from Operations | -37.90% | -47.51% | -109.23% | -14.85% | -64.69% |
| Capital Expenditure | -166.67% | -- | -- | -66.67% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -166.67% | -- | -- | -66.67% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 65.62% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 94.34% | -55.12% | -207.84% | -- | -80.07% |
| Cash from Financing | -94.43% | 278.05% | -207.84% | -- | 64.37% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -116.25% | -33.61% | -110.89% | -29.67% | 64.30% |